Multiple Myeloma | What Clinicians Want to Know About Anti-CD38 Antibodies in the Management of Multiple Myeloma (Companion Faculty Lecture)
Research To Practice | Oncology Videos · Dr. Neil Love
October 9, 202328m 48s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring a slide presentation and related discussion from Dr Philippe Moreau, including the following topics:
- General overview of anti-CD38 antibodies in therapy for multiple myeloma (MM) (0:00)
- Anti-CD38 antibodies as part of first-line therapy for transplant-ineligible patients with MM (2:35)
- Quadruplet versus triplet induction regimens with anti-CD38 antibodies for newly diagnosed, transplant-eligible patients with MM (7:44)
- Clinical trial data with anti-CD38 antibodies for patients with MM at first relapse (13:02)
- Treatment options for patients with MM at second relapse and beyond (18:09)
- Subcutaneous formulations of daratumumab and isatuximab; CD38 as a target for other therapeutic strategies (21:00)